Mayne Pharma Group Ltd (MYX) - Net Assets
Based on the latest financial reports, Mayne Pharma Group Ltd (MYX) has net assets worth AU$370.28 Million AUD (≈ $262.00 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.01 Billion ≈ $717.90 Million USD) and total liabilities (AU$644.32 Million ≈ $455.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Mayne Pharma Group Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$370.28 Million |
| % of Total Assets | 36.5% |
| Annual Growth Rate | 66.89% |
| 5-Year Change | -52.01% |
| 10-Year Change | -1.58% |
| Growth Volatility | 14700.06 |
Mayne Pharma Group Ltd - Net Assets Trend (2006–2025)
This chart illustrates how Mayne Pharma Group Ltd's net assets have evolved over time, based on quarterly financial data. Also explore MYX current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Mayne Pharma Group Ltd (2006–2025)
The table below shows the annual net assets of Mayne Pharma Group Ltd from 2006 to 2025. For live valuation and market cap data, see MYX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$370.28 Million ≈ $262.00 Million |
-18.47% |
| 2024-06-30 | AU$454.19 Million ≈ $321.37 Million |
-28.40% |
| 2023-06-30 | AU$634.36 Million ≈ $448.85 Million |
+13.86% |
| 2022-06-30 | AU$557.12 Million ≈ $394.20 Million |
-27.79% |
| 2021-06-30 | AU$771.58 Million ≈ $545.94 Million |
-25.97% |
| 2020-06-30 | AU$1.04 Billion ≈ $737.50 Million |
+2.78% |
| 2019-06-30 | AU$1.01 Billion ≈ $717.52 Million |
-17.90% |
| 2018-06-30 | AU$1.24 Billion ≈ $873.95 Million |
-5.89% |
| 2017-06-30 | AU$1.31 Billion ≈ $928.62 Million |
+248.84% |
| 2016-06-30 | AU$376.22 Million ≈ $266.20 Million |
+16.77% |
| 2015-06-30 | AU$322.20 Million ≈ $227.98 Million |
+102.29% |
| 2014-06-30 | AU$159.27 Million ≈ $112.70 Million |
+31.75% |
| 2013-06-30 | AU$120.89 Million ≈ $85.54 Million |
+295.06% |
| 2012-06-30 | AU$30.60 Million ≈ $21.65 Million |
+26.58% |
| 2011-06-30 | AU$24.17 Million ≈ $17.10 Million |
-5.38% |
| 2010-06-30 | AU$25.55 Million ≈ $18.08 Million |
+231.63% |
| 2009-06-30 | AU$7.70 Million ≈ $5.45 Million |
-32.65% |
| 2008-06-30 | AU$11.44 Million ≈ $8.09 Million |
-21.19% |
| 2007-06-30 | AU$14.51 Million ≈ $10.27 Million |
+65874.10% |
| 2006-06-30 | AU$22.00K ≈ $15.57K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mayne Pharma Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 104098200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$1.23 Billion | 331.09% |
| Other Comprehensive Income | AU$185.29 Million | 50.04% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$370.28 Million | 100.00% |
Mayne Pharma Group Ltd Competitors by Market Cap
The table below lists competitors of Mayne Pharma Group Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BICO Group AB
ST:BICO
|
$159.82 Million |
|
Clavister Holding AB (publ.)
ST:CLAV
|
$159.89 Million |
|
Kao Fong Machinery Co Ltd
TWO:4510
|
$160.06 Million |
|
Bank Capital Indonesia Tbk
JK:BACA
|
$160.18 Million |
|
Ilyang Pharmaceutical Co Ltd
KO:007575
|
$159.79 Million |
|
UmweltBank AG
XETRA:UBK
|
$159.79 Million |
|
Muhak Co. Ltd
KO:033920
|
$159.75 Million |
|
Orogen Royalties Inc
V:OGN
|
$159.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mayne Pharma Group Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 454,188,000 to 370,283,000, a change of -83,905,000 (-18.5%).
- Net loss of 93,836,000 reduced equity.
- Share repurchases of 148,000 reduced equity.
- Other comprehensive income increased equity by 11,318,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-93.84 Million | -25.34% |
| Share Repurchases | AU$148.00K | -0.04% |
| Other Comprehensive Income | AU$11.32 Million | +3.06% |
| Other Changes | AU$-1.24 Million | -0.33% |
| Total Change | AU$- | -18.47% |
Book Value vs Market Value Analysis
This analysis compares Mayne Pharma Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.59x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 407.68x to 0.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-06-30 | AU$0.01 | AU$2.78 | x |
| 2007-06-30 | AU$4.71 | AU$2.78 | x |
| 2008-06-30 | AU$2.15 | AU$2.78 | x |
| 2009-06-30 | AU$1.45 | AU$2.78 | x |
| 2010-06-30 | AU$2.87 | AU$2.78 | x |
| 2011-06-30 | AU$2.27 | AU$2.78 | x |
| 2012-06-30 | AU$2.87 | AU$2.78 | x |
| 2013-06-30 | AU$5.49 | AU$2.78 | x |
| 2014-06-30 | AU$4.97 | AU$2.78 | x |
| 2015-06-30 | AU$8.75 | AU$2.78 | x |
| 2016-06-30 | AU$9.00 | AU$2.78 | x |
| 2017-06-30 | AU$17.84 | AU$2.78 | x |
| 2018-06-30 | AU$16.77 | AU$2.78 | x |
| 2019-06-30 | AU$13.66 | AU$2.78 | x |
| 2020-06-30 | AU$13.57 | AU$2.78 | x |
| 2021-06-30 | AU$9.78 | AU$2.78 | x |
| 2022-06-30 | AU$7.19 | AU$2.78 | x |
| 2023-06-30 | AU$7.63 | AU$2.78 | x |
| 2024-06-30 | AU$5.70 | AU$2.78 | x |
| 2025-06-30 | AU$4.68 | AU$2.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mayne Pharma Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.99%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 2.74x
- Recent ROE (-25.34%) is below the historical average (-10.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -12.57% | -1301.80% | 0.01x | 1.07x | AU$-3.28 Million |
| 2008 | -30.36% | -423.09% | 0.07x | 1.02x | AU$-4.62 Million |
| 2009 | -48.82% | -361.71% | 0.13x | 1.04x | AU$-4.53 Million |
| 2010 | 12.73% | 8.78% | 0.52x | 2.78x | AU$698.14K |
| 2011 | 6.95% | 3.44% | 0.91x | 2.22x | AU$-738.40K |
| 2012 | 20.11% | 12.05% | 0.95x | 1.76x | AU$3.09 Million |
| 2013 | -2.35% | -3.46% | 0.35x | 1.93x | AU$-14.93 Million |
| 2014 | 13.37% | 14.97% | 0.53x | 1.67x | AU$5.36 Million |
| 2015 | 2.50% | 5.53% | 0.27x | 1.70x | AU$-23.33 Million |
| 2016 | 10.27% | 13.98% | 0.17x | 4.28x | AU$980.10K |
| 2017 | 6.79% | 15.47% | 0.30x | 1.47x | AU$-41.82 Million |
| 2018 | -10.92% | -25.27% | 0.29x | 1.49x | AU$-256.63 Million |
| 2019 | -27.71% | -53.16% | 0.32x | 1.62x | AU$-379.98 Million |
| 2020 | -8.94% | -20.30% | 0.25x | 1.76x | AU$-196.54 Million |
| 2021 | -27.13% | -52.00% | 0.27x | 1.90x | AU$-285.26 Million |
| 2022 | -49.81% | -179.00% | 0.12x | 2.28x | AU$-337.76 Million |
| 2023 | 18.48% | 63.87% | 0.15x | 1.97x | AU$53.81 Million |
| 2024 | -38.36% | -44.89% | 0.34x | 2.52x | AU$-219.65 Million |
| 2025 | -25.34% | -22.99% | 0.40x | 2.74x | AU$-130.86 Million |
Industry Comparison
This section compares Mayne Pharma Group Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $175,297,623
- Average return on equity (ROE) among peers: 13.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mayne Pharma Group Ltd (MYX) | AU$370.28 Million | -12.57% | 1.74x | $159.81 Million |
| Cyclopharm Ltd (CYC) | $12.46 Million | 7.15% | 0.32x | $61.87 Million |
| Ebos Group Ltd (EBO) | $5.62 Million | 39.72% | 1.24x | $2.51 Billion |
| Paragon Care Ltd (PGC) | $579.94K | 0.00% | 0.26x | $175.69 Million |
| Sigma Healthcare Ltd (SIG) | $682.53 Million | 7.20% | 0.58x | $22.95 Billion |
About Mayne Pharma Group Ltd
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more